주사제용 세파로스포린계 항생제 LB10522의 in vitro 및 in vivo 항균력

• 영문명: In Vitro and in Vivo Antibacterial Activities of a New Parenteral Cephalosporin, LB10522
• 발행기관: 대한약학회
• 저자명: 백경숙(Kyung Sook Park) 오정인(Jeong In Oh) 김무용(Mu Yong Kim) 김인철(In Chull Kim) 곽진환(Jin Hwan Kwak)
• 간행물 정보: 『약학회지』제40권 제1호 (1996년), 95~101쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 1996.02.28

영문 초록

The in vitro antibacterial activities of LB10522, a new catechol-substituted cephalosporin, were compared with those of cefpirome, ceftazidime, ceftriaxone, and cefoperazone against clinical isolates and laboratory standard anaerobes. LB10522 had broad spectrum antibacterial activities against both gram-positive and gram-negative microorganisms. It was most active against gram-positve bacteria among the reference cephalosporins tested. Against gram-negative strains such as the family Enterobacteriaceae, LB10522 showed an activity comparable to that of cefpirome. But LB10522 was more potent than ceftazidime, ceftriaxone and cefoperazone. In particular, Pseudomonas aeruginosa was highly susceptible to LB10522, which was 32-fold and 64-fold more active than ceftazidime and cefpirome, respectively. Against anaerobic strains, the activity of LB10522 was similar to those of reference compounds. LB10522 exhibited potent therapeutic activities against experimental local infections in mice. The therapeutic effect of LB10522 against urinary tract infection (UTI) caused by P. aeruginosa 1912E in mice was superior to that of cefpirome. Against experimental respiratory tract infection (RTI) caused by K. pneumoniae DT-S in mice, LB10522 was as effective as cefpirome. The in vivo efficacy of LB10522 was correlated well with its in vitro activity.

키워드

Cephalosporin Clinical isolates Anaerobes RTI(Respiratoty Tract Infection) UTI(Urinary Tract Infection) LB10522.